Procyon Biopharma receives $980,000 from IRAP

Guest Contributor
January 24, 2006

Montreal's Procyn Biopharma Inc has received a repayable contribution of $980,000 from the Industrial Research Assistance Program for the early clinical development of PPL-100, a protease inhibitor for the treatment of drug-resistant HIV. Procyon received Health Canada approval last December to initiate the first-in-human Phase I clinical trials for PPL-100, an anti-viral agent with a high genetic barrier and favourable cross-resistance profile. Repayment is scheduled to begin in 2009 based on revenues generated by Procyon....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.